Aspirin Resistance in Cardiovascular Disease: Pathogenesis, Diagnosis and Clinical Impact (Journal article)

Papathanasiou, A./ Goudevenos, J./ Tselepis, A. D.

Full metadata record
DC FieldValueLanguage
dc.contributor.authorPapathanasiou, A.en
dc.contributor.authorGoudevenos, J.en
dc.contributor.authorTselepis, A. D.en
dc.rightsDefault Licence-
dc.subjectacetylsalicylic aciden
dc.subjectantiplatelet medicationen
dc.subjectacute myocardial-infarctionen
dc.subjectlow-dose aspirinen
dc.subjectnonsteroidal antiinflammatory drugsen
dc.subjectperipheral arterial-diseaseen
dc.subjectchronic heart-failureen
dc.subjectst-segment elevationen
dc.subjectpercutaneous coronary interventionen
dc.subjectventricular ejection fractionsen
dc.subjectincreased platelet reactivityen
dc.subjectassociation task-forceen
dc.titleAspirin Resistance in Cardiovascular Disease: Pathogenesis, Diagnosis and Clinical Impacten
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondary<Go to ISI>://000265789400006-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.abstractAspirin is the cornerstone of treatment in patients with coronary artery disease. However, several studies investigating the in vitro response of platelets to the administration of aspirin showed this response to be variable, with some patients exhibiting non-responsiveness or resistance. Aspirin resistance may be categorised as either 'laboratory' or 'clinical'. Laboratory aspirin resistance is defined as the failure of aspirin to inhibit the production of thromboxane A(2) (TxA(2)) by platelets or to inhibit platelet activation that depends on TxA(2) production. Clinical aspirin resistance is defined as the failure to prevent the occurrence of atherothrombotic ischaemic episodes in patients to whom it is administered. So far, there is no generally accepted method for the ex vivo evaluation of platelet activation or for assessing the degree of platelet activation following aspirin administration and data concerning the clinical impact of aspirin resistance are conflicting. For these reasons it is not possible to suggest specific guidelines for the treatment of patients who show high levels of platelet activation or a low level of platelet inhibition after treatment with aspirin. The aim of this review is to present data from laboratory and clinical studies that are related to resistance to aspirin, and to discuss the possible causes, the clinical significance, and the ways of managing such resistance at a clinical level.en
heal.journalNameCurr Pharm Desen
heal.journalTypepeer reviewed-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.

 Please use this identifier to cite or link to this item:
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.